[ET Net News Agency, 1 June 2021] Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
(02196) said its subsidiary Fosun Health has agreed to sell 75% equity interest in Taizhou
Medical for a consideration of approximately RMB553.4671 million. Upon the completion, the
group will cease to hold any equity interest in Taizhou Medical.
The principal business of Taizhou Medical comprises healthcare services and elderly care
services, of which the main asset is Taizhou Zhedong Hospital under construction. (RC)